Logo

AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)

Share this

AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)

Shots:

  • Kyowa Kirin to receives upfront- regulatory & commercial milestones. AstraZeneca to get global rights to develop & commercialize Fasenra (beralizumab) for all indication across 14 Asian countries including Japan
  • In Mar-2017 AstraZeneca & Kyowa Kirin collaborated to develop & commercialize Fasenra (beralizumab) for severe asthma and chronic obstructive pulmonary disease (COPD) in Asia
  • Fasenra (beralizumab- SC- 30mg- FD) is a mAb admninistered using prefilled syringe targeting NKcells and has received FDA’s ODD for the hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA)

Click here to read full press release/ article 

Ref: Kyowa Hakko Kirin | Image: AstraZeneca 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions